Story perspectives

Stiffening Tumors Boosts T-Cell Killing, Enhances CAR-T Therapy

7/7/2026

Summary

Cytotoxic T Force

US researchers reported that cytotoxic T cells apply mechanical force to increase target cell killing.
Experiments showed soft cancer cells evade perforin-mediated killing by cytotoxic lymphocytes.
Depleting cholesterol stiffens cancer cells and improves the efficacy of adoptive T-cell immunotherapy.
Increased matrix stiffness drives tumor progression by amplifying integrin signaling and suppresses ATP-triggered sustained calcium influx in breast cancer cells.
Ultrasound mechanogenetics primes tumors, leading to improved CAR-T therapy outcomes.

Summary

IL-24 Boosts CAR-T

IL-24 enhances CAR-T cell therapy effectiveness by targeting tumor stemness (2024).
Long-term follow-up shows sustained remissions in leukemia and glioblastoma, with notable regression reported in a 2016 trial.
Engineered adeno-associated virus 3 vectors reduce serum antibody reactivity, improving delivery for hepatocellular carcinoma treatments (2021).
Lipid-nanoparticle CRISPR-Cas9 editing is explored as a non-viral cancer-therapy platform, demonstrated in a 2020 report.

1 of 2

Cytotoxic T Force

US researchers reported that cytotoxic T cells apply mechanical force to increase target cell killing.
Experiments showed soft cancer cells evade perforin-mediated killing by cytotoxic lymphocytes.
Depleting cholesterol stiffens cancer cells and improves the efficacy of adoptive T-cell immunotherapy.
Increased matrix stiffness drives tumor progression by amplifying integrin signaling and suppresses ATP-triggered sustained calcium influx in breast cancer cells.
Ultrasound mechanogenetics primes tumors, leading to improved CAR-T therapy outcomes.

1 / 2